Cnf1 Variants Endowed with the Ability to Cross the Blood–Brain Barrier: A New Potential Therapeutic Strategy for Glioblastoma
Authors:
- Andrea ColarussoACAndrea Colarusso
- Zaira MarocciaZMZaira Maroccia
- Ermenegilda ParrilliErmenegilda Parrilli
- Elena Angela Pia GerminarioEGElena Angela Pia Germinario
- Andrea FortunaAFAndrea Fortuna
- Stefano LoizzoSLStefano Loizzo
- Laura RicceriLRLaura Ricceri
- Maria Luisa TutinoMaria Luisa Tutino
- Carla FiorentiniCarla Fiorentini
- Alessia FabbriAlessia Fabbri
Open Access
Abstract
Among gliomas, primary tumors originating from glial cells, glioblastoma (GBM) identified as WHO grade IV glioma, is the most common and aggressive malignant brain tumor. We have previously shown that the Escherichia coli protein toxin cytotoxic necrotizing factor 1 (CNF1) is remarkably effective as an anti-neoplastic agent in a mouse model of glioma, reducing the tumor volume, increasing survival, and maintaining the functional properties of peritumoral neurons. However, being unable to cross the blood–brain barrier (BBB), CNF1 requires injection directly into the brain, which is a very invasive administration route. Thus, to overcome this pitfall, we designed a CNF1 variant characterized by the presence of an N-terminal BBB-crossing tag. The variant was produced and we verified whether its activity was comparable to that of wild-type CNF1 in GBM cells. We investigated the signaling pathways engaged in the cell response to CNF1 variants to provide preliminary data to the subsequent studies in experimental animals. CNF1 may represent a novel avenue for GBM therapy, particularly because, besides blocking tumor growth, it also preserves the healthy surrounding tissue, maintaining its architecture and functionality. This renders CNF1 the most interesting candidate for the treatment of brain tumors, among other potentially effective bacterial toxins.Keywords
Funding Information
- La fabbrica dei sogni 2 - New developments for Rett syndrome (---)
This publication has 31 references indexed in Scilit:
- Correction: CNF1 Increases Brain Energy Level, Counteracts Neuroinflammatory Markers and Rescues Cognitive Deficits in a Murine Model of Alzheimer's DiseasePLOS ONE, 2013
- CNF1 Increases Brain Energy Level, Counteracts Neuroinflammatory Markers and Rescues Cognitive Deficits in a Murine Model of Alzheimer's DiseasePLOS ONE, 2013
- High Prevalence of Mucosa-Associated E. coli Producing Cyclomodulin and Genotoxin in Colon CancerPLOS ONE, 2013
- Modulation of RhoGTPases Improves the Behavioral Phenotype and Reverses Astrocytic Deficits in a Mouse Model of Rett SyndromeNeuropsychopharmacology, 2011
- Mitochondrial fusion and fission in cell life and deathNature Reviews Molecular Cell Biology, 2010
- Escherichia coli Cytotoxic Necrotizing Factor 1 (CNF1): Toxin Biology, in Vivo Applications and Therapeutic PotentialToxins, 2010
- Cleavage of Escherichia coli Cytotoxic Necrotizing Factor 1 Is Required for Full Biologic ActivityInfection and Immunity, 2009
- Involvement of the low‐density lipoprotein receptor‐related protein in the transcytosis of the brain delivery vector Angiopep‐2Journal of Neurochemistry, 2008
- Barreling through the membraneNature Structural & Molecular Biology, 2004
- Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4Nature, 1970